3 Undervalued Pharmaceuticals Stocks for Thursday, September 17
Discover the top 3 undervalued Pharmaceuticals stocks for Thursday, September 17 based on AAII’s Stock Grades.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. The company was incorporated in 2006 and is based in Parsippany, New Jersey.
Commentary & Analysis
Why CorMedix Inc.’s (CRMD) Stock Is Up 5.61%
As of Tuesday, August 18, CorMedix Inc.’s CRMD share price has surged by 5.61%, which has investors questioning if this is right time to sell.Jenna Brashear
6 Undervalued Pharmaceuticals Stocks for Monday, August 17
Discover the top 6 undervalued Pharmaceuticals stocks for Monday, August 17 based on AAII’s Stock Grades.Tudor Pop
Why CorMedix Inc.’s (CRMD) Stock Is Up 6.90%
As of Monday, August 17, CorMedix Inc.’s CRMD share price has surged by 6.90%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why CorMedix Inc.’s (CRMD) Stock Is Up 22.89%
As of Thursday, August 13, CorMedix Inc.’s CRMD share price has surged by 22.89%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Financial Summary
| Share Statistics | CRMD | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $575.2 | $519.2 | 39% |
|
| Shares Out (Mil) | 92.5 | 42.8 | 60% |
|
| Institutional Ownership | 86.8% | 82.8% | 54% |
|
| Float (Mil) | 65.9 | 44.4 | 53% |
|
| Beta | 1.50 | 0.71 | 82% |
|
| Avg Daily Volume (000s) | 948 | 394 | 69% |
|
| Price Change (52-week) |
(34.5%) | 60.2% | 27% |
|
| Growth | CRMD | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 335.1% | 6.1% | 100% |
|
| Net Income (5yr) | 56.6% | (2.0%) | 95% |
|
| EPS (5yr) | 36.0% | 15.0% | 86 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 10.2% | (15.1%) | 70% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | $0.238 | $0.495 | $0.057 | |
| Month Ago EPS | na | na | na | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | (19.0%) | (75.7%) | (78.3%) | |
| Financials | CRMD | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $462 | $416 | 40% |
|
| Net Income (TTM) (Mil) | $187 | ($11) | 67% |
|
| EPS (TTM) | $2.378 | ($0.700) | 74% |
|
| Operating Cash Flow (TTM) (Mil) | $254 | ($7) | 62% |
|
| Net Cash Flow (TTM) (Mil) | $98 | $6 | 77% |
|
| Long-Term Debt (Q1) (Mil) | $148 | $6 | 47% |
|
| Enterprise Value (Q1) (Mil) | $493 | $494 | 34% |
|
| Valuation | CRMD | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.24 | 2.31 | 33% |
|
| P/E | 3.5 | 17.4 | 3% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 0.1 | 1.1 | 3% |
|
| Ratios | CRMD | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 90.2% | 69.4% | 94% |
|
| Net Margin | 40.5% | 3.2% | 95% |
|
| ROA | 32.4% | (22.2%) | 98% |
|
| ROE | 54.9% | (21.4%) | 93% |
|
| Liabilities to Assets | 49.0% | 32.8% | 41% |
|
| F-Score | 4 | 3 | 33% |
|
Passing Stock Screens
As of 10/9/2026, from a list of 60 stock screening strategies,
GURU STRATEGY
Magic Formula Screen
Factors: Value, Quality
Joel Greenblatt's investing approach is based on finding companies with high return on investment that are trading for less than they are worth.
| Performance Since Inception: | 7.0% |
| +/- S&P 500: | -0.5 |
